Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SanBio Company Limited
  6. Summary
    4592   JP3336750009

SANBIO COMPANY LIMITED

(4592)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/14/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
1161 1240 1242 1258 1283 Last
256000 474800 259400 172900 267300 Volume
+2.93% +6.80% +0.16% +1.29% +1.99% Change
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -5 553 M -48,7 M -48,7 M
Net cash position 2022 17 371 M 152 M 152 M
P/E ratio 2022 -12,2x
Yield 2022 -
Sales 2023 1 733 M 15,2 M 15,2 M
Net income 2023 -6 548 M -57,4 M -57,4 M
Net cash position 2023 9 538 M 83,6 M 83,6 M
P/E ratio 2023 -10,4x
Yield 2023 -
Capitalization 66 443 M 582 M 582 M
EV / Sales 2022 -
EV / Sales 2023 32,8x
Nbr of Employees 85
Free-Float 56,1%
More Financials
Company
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the... 
More about the company
Ratings of SanBio Company Limited
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about SANBIO COMPANY LIMITED
10/18SANBIO : Notice on Appointment of New Corporate Officer
PU
10/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
09/22SanBio Records Non-Operating Income, Extraordinary Loss in H1
MT
09/21SANBIO : Notice on Recording of Non-Operating Income and Extraordinary Loss
PU
09/16SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending ..
PU
09/14SANBIO : Consolidated Financial Results for the Six Months Ended July 31, 2021
PU
09/14SanBio Company Limited Announces Consolidated Earnings Results for the Six Months Ended..
CI
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Endi..
CI
09/14SANBIO : Notice Concerning Difference Between Consolidated Financial Forecasts and Actual ..
PU
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fi..
CI
08/31SANBIO : Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank, Ltd
PU
07/29SANBIO : Determination of Terms and Conditions of Stock Options
PU
07/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
07/01SANBIO : Notice Concerning Changes to Our Lineup of Corporate Officers
PU
07/01SanBio Company Limited Announces Executive Changes
CI
More news
News in other languages on SANBIO COMPANY LIMITED
09/22SanBio enregistre un résultat non opérationnel et une perte extraordinaire au premier s..
09/14SanBio Company Limited fournit des prévisions de bénéfices consolidés pour l'année fisc..
09/14SanBio Company Limited fournit des prévisions de bénéfices consolidés pour le premier s..
2019L'hypothèse d'un Brexit dur rend moroses les Bourses asiatiques
2019Tokyo chute malgré les records de Wall Street
More news
Chart SANBIO COMPANY LIMITED
Duration : Period :
SanBio Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANBIO COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 1 283,00 JPY
Average target price 2 660,00 JPY
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Keita Mori President, CEO & Representative Director
Toru Kawanishi Chairman
Bijan Nejadnik Chief Medical Officer & Executive Officer
Chris sanbio Horan Chief Technical Operations Officer
Akihiro Tsujimura COO, Representative Director & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SANBIO COMPANY LIMITED-4.04%582
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121